Developments DelMar Pharma enrolls first patient in adjuvant arm of Phase 2 glioblastoma trial DelMar Pharmaceuticals (NASDAQ:DMPI) treated the first MGMT-unmethylated glioblastoma multiforme (GBM) patient in the adjuvant trial arm of its Phase 2 study of VAL-083. This study arm will enroll up to 24 newly... July 24, 2019